Cancer Family
Gastric Neoplasm
CI-CAN-00000185Explore in graph →
Non-malignant720 active trials4 approved drugs55 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000185Explore in graph →
Clinical trials
3,258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04178460 | A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior Treatment | terminated | Phase 1 | 60 | Zai Lab (Shanghai) Co., Ltd.INDUSTRY | 1 | Jun 1, 2022 | clinicaltrials |
| NCT02102022 | Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on Hepatocellular Carcinoma | terminated | Phase 1 / Phase 2 | 140 | Polaris GroupINDUSTRY | 6 | Apr 25, 2022 | clinicaltrials |
| NCT03707028 | A Study to Evaluate Safety, Tolerability, and Efficacy Profile of Rivoceranib With Paclitaxel in Advanced Gastric or Gastroesophageal Junction Cancer | terminated | Phase 1 / Phase 2 | 12 | Elevar TherapeuticsINDUSTRY | 1 | Apr 11, 2022 | clinicaltrials |
| NCT02420795 | Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | terminated | Phase 1 / Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 4, 2022 | clinicaltrials |
| NCT03735290 | A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With Checkpoint Inhibitor (CPI) in Patients With ADvanced Cancer(ILIAD) | terminated | Phase 1 | 21 | MendusINDUSTRY | 1 | Mar 16, 2022 | clinicaltrials |
| NCT04099277 | A Study of LY3435151 in Participants With Solid Tumors | terminated | Phase 1 | 2 | Eli Lilly and CompanyINDUSTRY | 2 | Aug 31, 2021 | clinicaltrials |
| NCT02908451 | A Study of AbGn-107 in Patients With Gastric, Colorectal, Pancreatic or Biliary Cancer | terminated | Phase 1 | 39 | AbGenomics B.V Taiwan BranchINDUSTRY | 2 | Jul 13, 2021 | clinicaltrials |
| NCT00064259 | A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction Cancer | terminated | Phase 1 / Phase 2 | 15 | National Cancer Institute (NCI)NIH | 1 | Feb 17, 2021 | clinicaltrials |
| NCT02757391 | CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors | terminated | Phase 1 | 1 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 30, 2020 | clinicaltrials |
| NCT03957096 | A Safety Study of SGN-CD47M in Patients With Solid Tumors | terminated | Phase 1 | 16 | Seagen Inc.INDUSTRY | 1 | Sep 17, 2020 | clinicaltrials |
| NCT02346955 | Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001) | terminated | Phase 1 | 27 | Famewave Ltd.INDUSTRY | 2 | Aug 27, 2020 | clinicaltrials |
| NCT01249443 | Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection | terminated | Phase 1 | 17 | AIDS Malignancy ConsortiumNETWORK | 1 | Jul 29, 2020 | clinicaltrials |
| NCT03511222 | Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors | terminated | Phase 1 | 16 | Washington University School of MedicineOTHER | 1 | Jul 29, 2020 | clinicaltrials |
| NCT02512237 | A Dose-escalation Study of ARX788, IV Administered in Subjects With Advanced Cancers With HER2 Expression | terminated | Phase 1 | 9 | Zhejiang Medicine Co., Ltd.INDUSTRY | 2 | Jun 5, 2020 | clinicaltrials |
| NCT02318901 | Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer(PembroMab) | terminated | Phase 1 / Phase 2 | 16 | Western Regional Medical CenterOTHER | 1 | Oct 21, 2019 | clinicaltrials |
| NCT02952989 | A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors | terminated | Phase 1 | 47 | Seagen Inc.INDUSTRY | 1 | Jul 19, 2019 | clinicaltrials |
| NCT03253185 | A Study of SC-007 in Subjects With Advanced Cancer | terminated | Phase 1 | 7 | AbbVieINDUSTRY | 1 | Apr 27, 2018 | clinicaltrials |
| NCT01355302 | E7050 in Combination With Cisplatin and Capecitabine Versus Cisplatin and Capecitabine Alone in Patients With Advanced or Metastatic Solid Tumors and Previously Untreated Gastric Cancer | terminated | Phase 1 / Phase 2 | 7 | Eisai Inc.INDUSTRY | 4 | May 15, 2017 | clinicaltrials |
| NCT02207959 | Gastric In Vivo Study | terminated | Phase 1 | 8 | Susana GonzalezOTHER | 1 | May 2, 2017 | clinicaltrials |
| NCT02391038 | MLN0264 in Previously Treated Asian Participants With Advanced Gastrointestinal Carcinoma or Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Guanylyl Cyclase C | terminated | Phase 1 | 12 | Millennium Pharmaceuticals, Inc.INDUSTRY | 3 | Mar 29, 2017 | clinicaltrials |
| NCT00524186 | Sunitinib, Irinotecan, Fluorouracil, and Leucovorin In Treating Patients With Advanced Stomach Cancer or Gastroesophageal Cancer | terminated | Phase 1 | 23 | Roswell Park Cancer InstituteOTHER | 1 | Jun 21, 2016 | clinicaltrials |
| NCT02720926 | Study of TKI 258 in Combination With Xeloda and Oxaliplatin in Advanced Colorectal and Gastric Cancer | terminated | Phase 1 | 3 | National Cancer Centre, SingaporeOTHER | 1 | Mar 28, 2016 | clinicaltrials |
| NCT00130936 | Study of Epirubicin (Pharmorubicin®), Carboplatin (Paraplatin®) and Capecitabine (Xeloda®) (ECC) in the Treatment of Unresectable Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer With Pharmacogenetic Correlates | terminated | Phase 1 / Phase 2 | 50 | AHS Cancer Control AlbertaOTHER | 1 | Feb 15, 2016 | clinicaltrials |
| NCT02283359 | Selinexor in Combination With Irinotecan in Adenocarcinoma of Stomach and Distal Esophagus | terminated | Phase 1 | 3 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 15, 2016 | clinicaltrials |
| NCT01716546 | Trial of Panitumumab Cisplatin, Fluourouracil and Docetaxel in Locally Advanced or Metastatic Gastric Cancer | terminated | Phase 1 / Phase 2 | 51 | Hellenic Oncology Research GroupOTHER | 1 | Oct 8, 2015 | clinicaltrials |
| NCT00023634 | S0114 Vaccine Therapy in Treating Patients With Gastric, Prostate, or Ovarian Cancer | terminated | Phase 1 | 14 | SWOG Cancer Research NetworkNETWORK | 1 | Mar 6, 2015 | clinicaltrials |
| NCT00539968 | A Study to Evaluate the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel (Study P04467AM1)(TERMINATED) | terminated | Phase 1 / Phase 2 | 5 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Feb 5, 2015 | clinicaltrials |
| NCT00511576 | Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer Tumors | terminated | Phase 1 | 54 | Mirati Therapeutics Inc.INDUSTRY | 1 | Jan 8, 2015 | clinicaltrials |
| NCT01233505 | Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors | terminated | Phase 1 | 16 | National Cancer Institute (NCI)NIH | 1 | Apr 2, 2014 | clinicaltrials |
| NCT00165594 | A Study of E7070 in Patients With Gastric Cancer | terminated | Phase 1 / Phase 2 | 50 | Eisai Co., Ltd.INDUSTRY | 1 | Jan 23, 2014 | clinicaltrials |
| NCT01705340 | Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery | terminated | Phase 1 | 60 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT01611506 | Combination Chemotherapy, Cetuximab and Radiation for Patients With Localized Gastric Cancer | terminated | Phase 1 / Phase 2 | 1 | Dr Anna Dorothea WagnerOTHER | 1 | Jan 9, 2013 | clinicaltrials |
| NCT01212887 | Treated Blood Cells, Cyclophosphamide, Fludarabine Phosphate, and Aldesleukin in Treating Patients With Cancer | terminated | Phase 1 | 14 | Cancer Research UKOTHER | 1 | Feb 28, 2012 | clinicaltrials |
Data updated 22 days agoSource updated Jun 1, 2022source: clinicaltrials